Yvette Van Norden

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

Journal: Haematologica

Published: July 10, 2025

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.

Journal: British journal of haematology

Published: January 27, 2025

Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review.

Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review.

Journal: JAMA oncology

Published: August 29, 2024

Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".

Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 07, 2023

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.

Journal: Cancer medicine

Published: August 04, 2023

Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.

Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 03, 2023

Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.

Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 28, 2022

HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial.

HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial.

Journal: BMC cancer

Published: December 23, 2022

Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.

Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.

Journal: Frontiers in oncology

Published: December 02, 2022

Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma.

Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 25, 2022

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis.

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis.

Journal: HemaSphere

Published: September 07, 2022

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Journal: Leukemia

Published: May 24, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026